The Role of the Pharmacist in a Collaborative Care Model

October’s hematology coverage highlighted first-line pirtobrutinib, questions about myeloma treatment duration and early intervention, and pharmacists’ roles in medication safety and access.

Study shows prior authorization and high out-of-pocket costs drive prescription abandonment, limiting Medicare Part D blood cancer treatment access to oral anticancer medications.

Jai Radhakrishnan, MD, MBBS, MS, FASN, discusses why IgG4-related kidney disease is often missed and what the MITIGATE subgroup data presented at ASN Kidney Week 2026 show.

Doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd (Voceryq) targets HPV-6 and HPV-11 to reduce the surgical burden for adults with the rare airway disease.

Before lung cancer therapy begins, diagnostic findings and treatment readiness shape care, creating opportunities for pharmacists to help patients start safely.

October’s oncology coverage highlighted new treatment options in rectal, breast, and prostate cancers, alongside longer-term survival findings and concerns about reduced-frequency immunotherapy.

ESMO 2026 lung cancer trials reshape first-line care with tarlatamab maintenance, stronger KRAS G12C results, and TROP2 ADC gains, raising pharmacy monitoring demands.

ESMO 2026 breast cancer updates show ribociclib boosts survival, while immunotherapy and extended endocrine therapy improve end points without longer overall survival.